Mumbai | July 22, 2026:
Synopsis
- Funding: Bioscan Research raises $1M seed round led by Unicorn India Ventures.
- Focus: Market expansion, regulatory approvals, product upgradation, and new IP creation.
- Growth: Achieved 5x growth in the last 12 months; aims for 3x growth in the next 12 months.
- Innovation: Flagship product CEREBO, a machine learning–powered NIRS device for early detection of traumatic brain injuries.
- Global Ambition: Plans to expand across India and overseas markets.
Announcement
Bioscan Research, an innovation-driven MedTech startup pioneering non-invasive diagnostic solutions for early disease detection, has raised $1 million in a seed round led by Unicorn India Ventures.
The funds will be strategically deployed for:
- Market expansion in India and abroad.
- Additional regulatory approvals.
- Product upgradation.
- New IP creation.
Company Vision & Innovation
Founded in 2017 by Anupam Lavania and Shilpa Malik, Bioscan Research integrates optics, electronics, mechanics, and software to develop affordable medical devices for early detection of brain injuries.
Its flagship product, CEREBO, is a machine learning–powered NIRS device designed for early detection of intracranial injuries at a pre-symptomatic phase. By enabling objective assessment, CEREBO ensures timely intervention within the golden period, improving patient outcomes even in the absence of visible symptoms.
Co-Founders, Bioscan Research: “We harness light to reveal what the eyes can’t see — giving doctors clarity, patients hope, and technology a heart. More than 50 million suffer from traumatic brain injury each year, and 50–90% of mild cases go unidentified. With this round, we will upgrade our product, bridge the limitations of traditional tools, and provide urgent care in India and internationally.”
Anil Joshi, Managing Partner, Unicorn India Ventures: “We have been investing in highly innovative MedTech companies consistently, as healthcare in India still has significant gaps. Bioscan Research is making it possible to detect intracranial haemorrhage non-invasively. The company has shown strong progress in the last 12 months, upgrading its technology solutions. We believe the market opportunity is huge, and Bioscan has built the right momentum to capitalise on this segment.”
Growth & Expansion Plans
- Witnessed 5x growth in the last 12 months.
- Targeting 3x growth in the next 12 months.
- Plans to expand across India and international markets.
About Bioscan Research
Bioscan Research is an ISO 13485:2016–certified MedTech company pioneering non-invasive diagnostic solutions for early disease detection. By integrating photonics, precision engineering, and machine learning–driven analytics, Bioscan is redefining how critical conditions are identified — enabling faster clinical decisions, improved outcomes, and more accessible care worldwide.
Its flagship product, CEREBO, is an advanced intracranial injury detector designed to assist in managing trauma patients, ensuring timely intervention within the golden period.
About Unicorn India Ventures
Founded in 2016 by Bhaskar Majumdar and Anil Joshi, Unicorn India Ventures (UIV) is a deeptech-focused early-stage fund investing in visionary startups.
- Fund I: ₹100 crore corpus, invested in 17 companies (SmartCoin, Open Bank, Sequretek, Pharmarack, Genrobotics, Clootrack, FutureCure).
- Fund II: ₹300 crore corpus, invested in 20 companies (Gamerji, Probus, Daalchini, Windo, Finsall).
- Fund III: Closed at ₹1,200 crore, surpassing target of ₹1,000 crore, focused on semiconductors, space tech, medical diagnostics, AI infrastructure, and India digital platforms.
- Recent Initiative: Launched ₹1,000 crore IITM Unicorn Frontier Fund I with IIT-Madras.
UIV has consistently delivered stellar exits and is recognised as one of India’s best-performing early-stage funds.
Submitted by PR Agency
